Francois Brisebois
Stock Analyst at Oppenheimer
(1.06)
# 3,454
Out of 4,814 analysts
89
Total ratings
27.27%
Success rate
-16.99%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $3.5 → $4 | $0.38 | +947.12% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $4.92 | +225.20% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $0.29 | +1,301.54% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $48.46 | +48.58% | 7 | Jan 22, 2025 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $5.65 | +254.30% | 4 | Dec 17, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $7.96 | +251.98% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $7.96 | +277.12% | 8 | Oct 31, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $35.34 | +361.23% | 4 | Oct 31, 2024 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Outperform | $56 → $59 | $28.50 | +107.02% | 5 | Oct 30, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $55 | $9.34 | +489.18% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $3.29 | +355.93% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $3.51 | +71.18% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $2.23 | +393.27% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $12.12 | +15.51% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $15 | $3.06 | +391.00% | 4 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $2.72 | +819.12% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $33.84 | +92.08% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $2.24 | +346.43% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.74 | +577.32% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $7.24 | +1,999.45% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $17.65 | +103.97% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $4 | $3.05 | +31.15% | 3 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $60 | $0.22 | +27,172.73% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $3.97 | +136,091.68% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8.5 | $2.58 | +230.10% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $3.39 | +224.48% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $1.60 | +1,025.00% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $3.39 | +1,377.10% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $1.40 | +231,328.57% | 1 | Feb 4, 2020 |
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $3.5 → $4
Current: $0.38
Upside: +947.12%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $4.92
Upside: +225.20%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $0.29
Upside: +1,301.54%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $48.46
Upside: +48.58%
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $5.65
Upside: +254.30%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $7.96
Upside: +251.98%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $7.96
Upside: +277.12%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $35.34
Upside: +361.23%
Harmony Biosciences Holdings
Oct 30, 2024
Reiterates: Outperform
Price Target: $56 → $59
Current: $28.50
Upside: +107.02%
Dyne Therapeutics
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $9.34
Upside: +489.18%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $3.29
Upside: +355.93%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $3.51
Upside: +71.18%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $2.23
Upside: +393.27%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $12.12
Upside: +15.51%
Jun 26, 2024
Maintains: Outperform
Price Target: $11 → $15
Current: $3.06
Upside: +391.00%
Jun 25, 2024
Initiates: Outperform
Price Target: $25
Current: $2.72
Upside: +819.12%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $33.84
Upside: +92.08%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $2.24
Upside: +346.43%
Apr 1, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.74
Upside: +577.32%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $7.24
Upside: +1,999.45%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $17.65
Upside: +103.97%
Apr 4, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $3.05
Upside: +31.15%
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $0.22
Upside: +27,172.73%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $3.97
Upside: +136,091.68%
Sep 7, 2022
Initiates: Outperform
Price Target: $8.5
Current: $2.58
Upside: +230.10%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $3.39
Upside: +224.48%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $1.60
Upside: +1,025.00%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $3.39
Upside: +1,377.10%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $1.40
Upside: +231,328.57%